IP Library Granted Patent US 9,821,090
Granted Patent B2
US 9,821,090 · App. 14/869,331 · Granted Nov 21, 2017

Electrodeposition coating for medical devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,821,090
App. No.
14/869,331
Granted
Nov 21, 2017
Kind
B2
Abstract

The present disclosure relates generally to coating medical devices. In particular, the present disclosure provides materials and methods for coating a portion of a balloon catheter with a pharmaceutical agent using electrodeposition techniques. Although angioplasty and stenting can be effective methods for treating vascular occlusions, restenosis remains a pervasiveness problem. Therefore, coating portions of a balloon catheter with a pharmaceutical agent that inhibits restenosis can reduce the likelihood of restenosis.

Claims (21)

1. A method for coating a scoring element of a balloon catheter, the method comprising:

introducing a coating solution comprising at least one polar pharmaceutical agent dissolved in a protic polar solvent into a coating apparatus, the coating apparatus comprising at least one electrically conductive scoring element functionally coupled to the coating apparatus and at least partially submerged into the coating solution; and

applying an electrical current to the coating apparatus to produce a charged scoring element that attracts the polar pharmaceutical agent to the charged scoring element, thereby depositing the polar pharmaceutical agent onto the charged scoring element.

2. The method of claim 1 , wherein the coating apparatus comprises a voltaic cell apparatus.

3. The method of claim 1 , wherein the coating apparatus comprises an electrolytic cell apparatus.

4. The method of claim 1 , wherein the coating apparatus comprises an electrophoretic apparatus.

5. The method of claim 1 , wherein the at least one scoring element is part of a network of scoring elements comprising an elastic metal cage.

6. The method of claim 1 , wherein the at least one scoring element is comprised of stainless steel, tantalum, platinum, cobalt chrome alloys, elgiloy or nitinol alloys.

7. The method of claim 1 , wherein the at least one polar pharmaceutical agent inhibits restenosis.

8. The method of claim 1 , wherein the at least one polar pharmaceutical agent inhibits cellular mitosis.

9. The method of claim 1 , wherein the at least one polar pharmaceutical agent comprises one or more of paclitaxel, docetaxel, DHA-paclitaxel, PG-paclitaxe, docosahexaenoic acid (DHA), rapamycin, or derivatives or combinations thereof.

10. The method of claim 1 , wherein the protic polar solvent comprises one or more of formic acid, n-butanol, isopropanol (IPA), ethanol, methanol, acetic acid, nitromethane, water, or combinations or derivatives thereof.

11. A method of manufacturing a coated scoring element for a balloon catheter, the method comprising:

obtaining at least one electrically conductive scoring element;

obtaining a coating solution comprising at least one polar pharmaceutical agent dissolved in a protic polar solvent;

introducing the coating solution into a coating apparatus comprising the at least one electrically conductive scoring element functionally coupled to the coating apparatus, wherein the at least one electrically conductive scoring element is at least partially submerged into the coating solution; and

applying an electrical current to the coating apparatus to produce a charged scoring element that attracts the polar pharmaceutical agent to the charged scoring element, thereby depositing the polar pharmaceutical agent onto the charged scoring element.

12. The method of claim 11 , wherein the coating apparatus comprises at least one of a voltaic cell apparatus, an electrolytic cell apparatus, and an electrophoretic apparatus.

13. The method of claim 11 , wherein the at least one polar pharmaceutical agent inhibits restenosis.

14. The method of claim 11 , wherein the at least one polar pharmaceutical agent comprises one or more of paclitaxel, docetaxel, DHA-paclitaxel, PG-paclitaxe, docosahexaenoic acid (DHA), rapamycin, or derivatives or combinations thereof.

15. The method of claim 11 , wherein the protic polar solvent comprises one or more of formic acid, n-butanol, isopropanol (IPA), ethanol, methanol, acetic acid, nitromethane, water, or combinations or derivatives thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0066 →
RELEASE OF SECURITY INTEREST Recorded Aug 10, 2017
From: MIDCAP FINANCIAL TRUST
To: THE SPECTRANETICS CORPORATION; ANGIOSCORE INC.
Reel/Frame 043518/0142 →
SECURITY INTEREST (REVOLVER) Recorded Dec 11, 2015
From: THE SPECTRANETICS CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037269/0425 →
SECURITY INTEREST (TERM) Recorded Dec 11, 2015
From: THE SPECTRANETICS CORPORATION
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 037269/0506 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2015
From: TRIFFO, THOMAS KELBY
To: THE SPECTRANETICS CORPORATION
Reel/Frame 037218/0657 →